| Caffeine and Methylliberine: A Human Pharmacokinetic Interaction Study | | 2022 |
| Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects | Clinical and Translational Science | 2021 |
| Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib | Frontiers in Pharmacology | 2021 |
| In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2020 |
| Non-vitamin K antagonist oral anticoagulants and sport | Minerva Cardioangiologica | 2020 |
| HPLC methods of fexofenadine quantitative analysis in rabbits’ liver | Farmatsiya I Farmakologiya | 2020 |
| Strategies for Incorporating Pharmacokinetic Studies into Oncology Phase I Trials | | 2020 |
| The possibility of prognosis of progesterone preparations interaction | Russian Journal of Human Reproduction | 2018 |
| 6. Role of Regulatory Science in New Drug Evaluation : Clinical Pharmacology and Pharmacokinetics | Japanese Journal of Clinical Pharmacology and Therapeutics | 2018 |
| Some Methodologic Considerations in the Assessment of Methods for Predicting Pharmacokinetic Drug-Drug Interactions | Clinical Pharmacology in Drug Development | 2017 |
| INFLUENCE OF VILDAGLIPTIN AND GLIQUIDONE COMBINATION ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY AND EXPRESSION ON THE BACKGROUND OF NORM AND IN EXPERIMENTAL ALLOXAN-INDUCED DIABETES MELLITUS TYPE 2 | I P Pavlov Russian Medical Biological Herald | 2016 |
| IN SILICO MODELING OF METABOLITE KINETICS | | |
| Views on the Therapeutic Needs of Older Adults | AAPS Advances in the Pharmaceutical Sciences Series | 2016 |
| Summary Report of Questionnaire Survey on Current Situation and Issues of Human Mass Balance Study Using Radioisotopes in Japan | Japanese Journal of Clinical Pharmacology and Therapeutics | 2015 |
| Renal Organic Cation and Anion Transport: From Physiology to Genes☆ | | 2014 |
| Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP) | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro CYP Induction Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2 | Methods in Pharmacology and Toxicology | 2014 |
| Membrane Transporters in ADME | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| In Vitro Kinetic Characterization of Transporter-Mediated Permeability | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| Drug-transporter interaction testing in drug discovery and development | World Journal of Pharmacology | 2013 |
| Pharmacokinetic drug interactions in liver disease: An update | World Journal of Gastroenterology | 2016 |
| Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism | Current Drug Metabolism | 2019 |
| Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients | PLoS ONE | 2016 |
| Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3 | Clinical and Translational Science | 2019 |
| Irreversible enzyme inhibition kinetics and drug-drug interactions | Methods in Molecular Biology | 2014 |
| Reversible mechanisms of enzyme inhibition and resulting clinical significance | Methods in Molecular Biology | 2014 |
| Case study 4. Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast | Methods in Molecular Biology | 2014 |
| Pharmacokinetics and ADME characterizations of antibody-drug conjugates | Methods in Molecular Biology | 2013 |
| Pharmacogenetics of membrane transporters: a review of current approaches | Methods in Molecular Biology | 2014 |
| Prediction of Hepatic Transporter-Mediated Drug–Drug Interaction from In Vitro Data | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| The Role of Transporters in Drug Development: Regulatory Science Perspectives from the FDA | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| INTEGRATED REACTIVE METABOLITE STRATEGIES | | |
| Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects | European Journal of Clinical Pharmacology | 2021 |
| The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator | Clinical Pharmacology in Drug Development | 2020 |
| Drug Interactions in the Liver | | 2020 |
| Replacing the eleven native tryptophans by directed evolution produces an active P-glycoprotein with site-specific, non-conservative substitutions | Scientific Reports | 2020 |
| Induction of Cytochrome P450 Systems | | 2020 |
| Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin | Scientific Reports | 2020 |
| Drug–Drug Interaction Studies | | 2020 |
| Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6 | Pharmacology Research and Perspectives | 2020 |
| Update on Therapeutic Protein-Drug Interaction: Information in Labeling | Clinical Pharmacokinetics | 2020 |
| Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans | Clinical and Translational Science | 2019 |
| Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[C]Methylpurine in Mice | Molecular Imaging and Biology | 2019 |
| Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis | Clinical Pharmacokinetics | 2019 |
| Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects | Antimicrobial Agents and Chemotherapy | 2019 |
| Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam | CPT: Pharmacometrics and Systems Pharmacology | 2019 |
| Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects | Clinical Drug Investigation | 2019 |
| EASL Clinical Practice Guidelines: Drug-induced liver injury | Journal of Hepatology | 2019 |
